Contact information
Research groups
Abdullah Khan
BSc (Hons) MRes PhD
Wellcome Trust Career Development Fellow, RDM Principal Investigator, MRC WIMM Group Leader
I'm a bioengineer interested in the basic processes that drive blood and immune cell production, and how these processes change in ageing and disease.
Biography and Background
I am a Group Leader in the MRC Molecular Haematology Unit at the MRC Weatherall Institute of Molecular Medicine, and a Wellcome Career Development Fellow. I’m interested in how blood and immune cells are produced, and particularly in how the systems that drive that production change with ageing and disease. To explore these questions, I engineer human model systems—mini organs or organoids.
I completed my PhD at the Institute of Cardiovascular Sciences, University of Birmingham, where I established a method for generating CRISPR-edited megakaryocytes (platelet-producing cells) from human induced pluripotent stem cells (iPSCs). I also developed a CRISPR-based approach to express photo-switchable tags in iPSCs and their progeny, enabling single-molecule imaging.
After completing my PhD in 2019, I was awarded a Sir Henry Wellcome Fellowship to develop a bone marrow organoid model for studying myeloid cancers. That award began at the University of Birmingham in 2020. In 2022, I undertook a six-month secondment at Boston Children’s Hospital (Harvard Medical School) in the Machlus/Italiano lab. I then joined Beth Psaila’s group at the MRC WIMM in 2023 and have since established my own research group, supported by a Wellcome Trust Career Development Award.
My recent research has focused on developing and applying vascularised human organoid models, with a particular emphasis on the bone marrow—the system responsible for blood and immune cell generation throughout adult life. I developed the first human bone marrow organoid model that captured the myeloid niche and, together with the Oxford team, have since advanced this system to better reflect the complexity of the native environment. We use these models to dissect healthy, aged, and diseased biology, and to develop human pre-clinical platforms that we believe will accelerate both basic and translational research.
More recently, we’ve begun coupling different organoid systems to model, for the first time, how injury to other tissues (e.g. cardiac tissue) drives immune cell recruitment, and how that immune response influences tissue injury and repair.
Outside of research, I’m overly fond of reading, music, eating, and dangling from precarious rock faces by my fingertips—questioning all my life choices.
Key publications
Human Multi-Organoid Platform to Model Immune Dynamics in Cardiac Injury and Disease.
Journal article
Reyat JS. et al, (2025), Circ Res, 137, 1133 - 1136
A proinflammatory stem cell niche drives myelofibrosis through a targetable galectin-1 axis.
Journal article
Li R. et al, (2024), Sci Transl Med, 16
Human Bone Marrow Organoids for Disease Modeling, Discovery, and Validation of Therapeutic Targets in Hematologic Malignancies.
Journal article
Khan AO. et al, (2023), Cancer Discov, 13, 364 - 385
Modelling the pathology and treatment of cardiac fibrosis in vascularised atrial and ventricular cardiac microtissues.
Journal article
Reyat JS. et al, (2023), Front Cardiovasc Med, 10
Recent publications
Engineering bone-marrow in a dish - a bloody business: Pre-clinical opportunities, translational use-cases, and a call for consensus.
Journal article
North D. et al, (2026), J Thromb Haemost
comBO: A combined human bone and lympho-myeloid bone marrow organoid for preclinical modeling of hematopoietic disorders.
Journal article
Shen Y. et al, (2026), Cell Stem Cell
Human Multi-Organoid Platform to Model Immune Dynamics in Cardiac Injury and Disease.
Journal article
Reyat JS. et al, (2025), Circ Res, 137, 1133 - 1136
Platelets sequester extracellular DNA, capturing tumor-derived and free fetal DNA.
Journal article
Murphy L. et al, (2025), Science, 389
comBO: A combined human bone and lympho-myeloid bone marrow organoid for pre-clinical modelling of haematopoietic disorders
Preprint
Shen Y. et al, (2025)
Belantamab Mafodotin Triggers Immune Invigoration in Multiple Myeloma Via Inflammatory and Immunogenic Cell Death
Preprint
Watson ECR. et al, (2025)
PITX2 deficiency leads to atrial mitochondrial dysfunction.
Journal article
Reyat JS. et al, (2024), Cardiovasc Res, 120, 1907 - 1923
A proinflammatory stem cell niche drives myelofibrosis through a targetable galectin-1 axis.
Journal article
Li R. et al, (2024), Sci Transl Med, 16
Generating human bone marrow organoids for disease modeling and drug discovery.
Journal article
Olijnik A-A. et al, (2024), Nat Protoc, 19, 2117 - 2146
The bone marrow is the primary site of thrombopoiesis.
Journal article
Asquith NL. et al, (2024), Blood, 143, 272 - 278
Tolerance of Whole Genome Duplication in Megakaryocytes, and Consequences for Their Genome Integrity
Poster
Rodriguez-Romera A. et al, (2024), BLOOD, 144, 421 - 422
Development of a First-in-Class CAR-T Therapy Against Calreticulin-Mutant Neoplasms and Evaluation in the Relevant Human Tissue Environment
Journal article
Rampotas A. et al, (2024), BLOOD, 144, 871 - 872
Implementing human bone marrow organoids to interrogate microenvironmental influences on the efficacy of blood cancer immunotherapies
Journal article
Wong ZC. et al, (2024), CANCER RESEARCH, 84
Blood Coagulation and Beyond: Position Paper from the Fourth Maastricht Consensus Conference on Thrombosis.
Journal article
Akbulut AC. et al, (2023), Thromb Haemost, 123, 808 - 839
Efficient megakaryopoiesis and platelet production require phospholipid remodeling and PUFA uptake through CD36.
Journal article
Barrachina MN. et al, (2023), Nat Cardiovasc Res, 2, 746 - 763
Efficient megakaryopoiesis and platelet production require phospholipid remodeling and PUFA uptake through CD36.
Journal article
Barrachina MN. et al, (2023), bioRxiv
Human Bone Marrow Organoids for Disease Modeling, Discovery, and Validation of Therapeutic Targets in Hematologic Malignancies.
Journal article
Khan AO. et al, (2023), Cancer Discov, 13, 364 - 385
Modelling the pathology and treatment of cardiac fibrosis in vascularised atrial and ventricular cardiac microtissues.
Journal article
Reyat JS. et al, (2023), Front Cardiovasc Med, 10
A pro-inflammatory stem cell niche drives myelofibrosis through a targetable galectin 1 axis
Preprint
Li R. et al, (2023)
The Bone Marrow Is the Primary Site of Thrombopoiesis
Conference paper
Asquith N. et al, (2023), BLOOD, 142
Platelets Sequester Extracellular DNA, Capturing Tumour-Derived and Free Fetal DNA
Poster
Murphy L. et al, (2023), BLOOD, 142
S100A8/A9 drives the formation of procoagulant platelets through GPIbα.
Journal article
Colicchia M. et al, (2022), Blood, 140, 2626 - 2643
Preferential uptake of SARS-CoV-2 by pericytes potentiates vascular damage and permeability in an organoid model of the microvasculature.
Journal article
Khan AO. et al, (2022), Cardiovasc Res, 118, 3085 - 3096
Rare missense variants in Tropomyosin-4 (TPM4) are associated with platelet dysfunction, cytoskeletal defects, and excessive bleeding.
Journal article
Stapley RJ. et al, (2022), J Thromb Haemost, 20, 478 - 485
Post-translational polymodification of β1-tubulin regulates motor protein localisation in platelet production and function.
Journal article
Khan AO. et al, (2022), Haematologica, 107, 243 - 259
A Case of ST-Elevation Myocardial Infarction With Right Bundle Branch Block, an Ominous Sign of Critical Coronary Occlusion.
Journal article
Basit H. et al, (2022), Cureus, 14